VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study

    NEXT STORY
    Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
    PREV STORY
    Global Immunotherapy Drugs Market (2020 to 2025) – Increased Demand for Personalized Medicines Presents Opportunities
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study

    author_avatar
    NASDAQ Market News

    UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs

    RA’ANANA, Israel, and NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. ...

    author_avatar
    NASDAQ Market News

    Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference

    author_avatar
    NASDAQ Market News